medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2019-4-35(410)-28-33medalphabet-1361Research ArticleСтатьиЭндотелиальная дисфункция как ранний предиктор атеросклерозаEndothelial dysfunction as early predictor of atherosclerosisПизовА. В.PizovA. V.

к. б. н., доцент

г. Ярославль

Yaroslavl

ПизовН. А.PizovN. A.

Кафедра нервных болезней с медицинской генетикой и нейрохирургией 

аспирант кафедры

г. Ярославль

Yaroslavl

СкачковаО. А.SkachkovaO. A.

Кафедра нервных болезней с медицинской генетикой и нейрохирургией 

аспирант кафедры

г. Ярославль

Yaroslavl

ПизоваН. В.PizovaN. V.

Кафедра нервных болезней с медицинской генетикой и нейрохирургией 

 д. м. н., проф. кафедры

г. Ярославль

Yaroslavl

ФГБОУ ВО «Ярославский государственный педагогический университет имени К. Д. Ушинского»РоссияYaroslavl State Pedagogical University n. a. K. D. UshinskyRussian FederationФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава РоссииРоссияYaroslavl State Mesical UniversityRussian Federation201921012020435Обозрение2833Copyright © Пизов А.В., Пизов Н.А., Скачкова О.А., Пизова Н.В., 20202020Пизов А.В., Пизов Н.А., Скачкова О.А., Пизова Н.В.Pizov A.V., Pizov N.A., Skachkova O.A., Pizova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1361

Сердечно‑сосудистые заболеваний в России лидируют в структуре общей смертности населения. Атеросклероз считается прогрессирующим воспалительным системным заболеванием. Подробно описана роль эндотелия в развитии атеросклеротического процесса. Показаны основные функции эндотелиоцитов в норме и при различных патологических состояниях. Представлены основные маркеры эндотелиальной дисфункции. Выделены локальные и системные факторы риска атеросклероза. Представлены данные о развитии атеросклеротического процесса во времени, факторах риска. Приведены собственные данные о частоте встречаемости атеросклеротических изменений в магистральных сосудах головы у лиц молодого возраста (до 45 лет) по результатам ультразвукового дуплексного сканирования при профессиональных осмотрах. Описаны основных направления коррекции эндотелиальной дисфункции.

Cardiovascular diseases in Russia are leading in the structure of total mortality. Atherosclerosis is considered a progressive inflammatory systemic disease. The role of endothelium in the development of the atherosclerotic process is described in detail. The main functions of endotheliocytes are normal and in various pathological conditions. The main markers of endothelial dysfunction are presented. Data on the development of the atherosclerotic process in time, risk factors are presented. Local and systemic risk factors for atherosclerosis are highlighted. Own data on the frequency of occurrence of atherosclerotic changes in the main vessels of the head in young people (up to 45 years) based on the results of ultrasonic duplex scanning during professional examinations are presented. The main directions of correction of endothelial dysfunction are described.

атеросклерозэндотелиальная функция и дисфункциябиомаркерыatherosclerosisendothelial function and dysfunctionbiomarkersReferencesГосударственный доклад о состоянии здоровья населения Российской Федерации в 2003 году. Здравоохранение Российской Федерации 2005; 5: 3–19.Государственный доклад о состоянии здоровья населения Российской Федерации в 2003 году. Здравоохранение Российской Федерации 2005; 5: 3–19.Piepoli M. F., Hoes A. W., Agewall S. et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016; 37 (29): 2315–2381.Piepoli M. F., Hoes A. W., Agewall S. et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016; 37 (29): 2315–2381.Hansson G. K. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine. 2005; 352 (16): 1685–1695.Hansson G. K. Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine. 2005; 352 (16): 1685–1695.Libby P., Hansson G. K. Inflammation and immunity in diseases of the arterial tree: players and layers. Circulation Research. 2015; 116 (2): 307–311.Libby P., Hansson G. K. Inflammation and immunity in diseases of the arterial tree: players and layers. Circulation Research. 2015; 116 (2): 307–311.Morbiducci U., Kok A. M., Kwak B. R., Stone P. H., Steinman D. A., Wentzel J. J. Atherosclerosis at arterial bifurcations: evidence for the role of haemodynamics and geometry. Thrombosis and Haemostasis. 2018; 115 (03): 484–492.Morbiducci U., Kok A. M., Kwak B. R., Stone P. H., Steinman D. A., Wentzel J. J. Atherosclerosis at arterial bifurcations: evidence for the role of haemodynamics and geometry. Thrombosis and Haemostasis. 2018; 115 (03): 484–492.O’Keeffe L.M., Simpkin A. J., Tilling K., et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: a prospective cohort study. Atherosclerosis. 2018; 278: 190–196.O’Keeffe L.M., Simpkin A. J., Tilling K., et al. Sex-specific trajectories of measures of cardiovascular health during childhood and adolescence: a prospective cohort study. Atherosclerosis. 2018; 278: 190–196.Дудкова В. А., Карпов Р. С. Атеросклероз сосудов сердца и головного мозга. Томск: STT 2002; 416 c.Дудкова В. А., Карпов Р. С. Атеросклероз сосудов сердца и головного мозга. Томск: STT 2002; 416 c.Das SK, Banerjee TK. Stroke: Indian Scenario. Circulation. 2008; 118: 2719–24.Das SK, Banerjee TK. Stroke: Indian Scenario. Circulation. 2008; 118: 2719–24.Sanchetee P. Stroke in Young. Editorial. J Indian Acad Clin Med. 2002; 3: 228–30.Sanchetee P. Stroke in Young. Editorial. J Indian Acad Clin Med. 2002; 3: 228–30.Prasad K, Singhal KK. Stroke in young: An Indian perspective. Neurol India. 2010; 58: 343–50.Prasad K, Singhal KK. Stroke in young: An Indian perspective. Neurol India. 2010; 58: 343–50.Lee TH, Hsu WC, Chen CJ, Chen ST. Etiologic study of young ischemic stroke in Taiwan. Stroke. 2002; 33: 1950–5.Lee TH, Hsu WC, Chen CJ, Chen ST. Etiologic study of young ischemic stroke in Taiwan. Stroke. 2002; 33: 1950–5.Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: The Helsinki Young Stroke Registry. Stroke. 2009; 40: 1195–203.Putaala J, Metso AJ, Metso TM, Konkola N, Kraemer Y, Haapaniemi E, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: The Helsinki Young Stroke Registry. Stroke. 2009; 40: 1195–203.Kyu H. H., Abate D., Abate K. H., et al. Global, regional, and national disability-adjusted lifeyears (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet. 2018; 392 (10159): 1859–1922.Kyu H. H., Abate D., Abate K. H., et al. Global, regional, and national disability-adjusted lifeyears (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet. 2018; 392 (10159): 1859–1922.Herrington W., Lacey B., Sherliker P., Armitage J., Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circulation Research. 2016; 118 (4): 535–546.Herrington W., Lacey B., Sherliker P., Armitage J., Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circulation Research. 2016; 118 (4): 535–546.Holman RL. Atherosclerosis — a pediatric nutrition problem? Am J Clin Nutr. 1961; 9: 565–569.Holman RL. Atherosclerosis — a pediatric nutrition problem? Am J Clin Nutr. 1961; 9: 565–569.Holman R. L., McGill H.C., Strong J. P., Geer J. C. The natural history of atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the 20th century. Am J Pathol 1958; 34: 209–235.Holman R. L., McGill H.C., Strong J. P., Geer J. C. The natural history of atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the 20th century. Am J Pathol 1958; 34: 209–235.Berenson G. S., Srinivasan S. R., Freedman D. S. et al. Atherosclerosis and its evolution in childhood. Am J Med Sci 1987; 294: 429–440.Berenson G. S., Srinivasan S. R., Freedman D. S. et al. Atherosclerosis and its evolution in childhood. Am J Med Sci 1987; 294: 429–440.Strong J. P., Malcom G. T., McMahan C.A. et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281: 727–735.Strong J. P., Malcom G. T., McMahan C.A. et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999; 281: 727–735.McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation. 2008; 117 (9): 1216–1227.McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation. 2008; 117 (9): 1216–1227.Wissler RW. USA Multicenter Study of the pathobiology of atherosclerosis in youth. Ann N Y Acad Sci. 1991; 623 (1): 26–39.Wissler RW. USA Multicenter Study of the pathobiology of atherosclerosis in youth. Ann N Y Acad Sci. 1991; 623 (1): 26–39.Lauer RM, Connor WE, Leaverton PE, et al. Coronary heart disease risk factors in school children: the Muscatine study. J Pediatr. 1975; 86 (5): 697–706.Lauer RM, Connor WE, Leaverton PE, et al. Coronary heart disease risk factors in school children: the Muscatine study. J Pediatr. 1975; 86 (5): 697–706.Akerblom HK, Viikari J, Uhari M, et al. Atherosclerosis precursors in Finnish children and adolescents. I. General description of the cross-sectional study of 1980, and an account of the children’s and families’ state of health. Acta Paediatr Scand Suppl. 1985; 318: 49–63.Akerblom HK, Viikari J, Uhari M, et al. Atherosclerosis precursors in Finnish children and adolescents. I. General description of the cross-sectional study of 1980, and an account of the children’s and families’ state of health. Acta Paediatr Scand Suppl. 1985; 318: 49–63.Пизова Н. В., Дружинин Д. С. Атеросклеротическое поражение сонных артерий у пациентов молодого возраста. Клиницист. 2014; 8 (1): 28–33.Пизова Н. В., Дружинин Д. С. Атеросклеротическое поражение сонных артерий у пациентов молодого возраста. Клиницист. 2014; 8 (1): 28–33.Lahoz C, Mostaza JM. Atherosclerosis as a systemic disease. Rev Esp Cardiol. 2007; 60 (2): 184–195.Lahoz C, Mostaza JM. Atherosclerosis as a systemic disease. Rev Esp Cardiol. 2007; 60 (2): 184–195.Доборджгинидзе Л. М., Грацианский Н. А. Дислипидемии: липиды и липопротеины, метаболизм и участие в атерогенезе. РМЖ. 2000; 8: 7.Доборджгинидзе Л. М., Грацианский Н. А. Дислипидемии: липиды и липопротеины, метаболизм и участие в атерогенезе. РМЖ. 2000; 8: 7.Дзяк Г. В., Коваль Е. А. Клинико-иммунологические критерии оценки прогноза и лечения атеросклероза и ревматизма. Журн АМН України 1998; 4 (1): 78–87.Дзяк Г. В., Коваль Е. А. Клинико-иммунологические критерии оценки прогноза и лечения атеросклероза и ревматизма. Журн АМН України 1998; 4 (1): 78–87.Kaski J. C., Zouridakis E. G. Inflammation, infection and acute coronary plaque events. Eur Heart J 2001; 3 (Suppl 1): 10–5.Kaski J. C., Zouridakis E. G. Inflammation, infection and acute coronary plaque events. Eur Heart J 2001; 3 (Suppl 1): 10–5.Maseri A., Cianflone D. Inflammation in acute coronary syndromes. Eur Heart J 2002; 4 (Suppl B): 8–13.Maseri A., Cianflone D. Inflammation in acute coronary syndromes. Eur Heart J 2002; 4 (Suppl B): 8–13.Luscher T. F., Tschudi M. R., Wenzel R. R., Noll G. Endothelial dysfunction and nitrogen monoxide (NO; nitric oxide). Internist (Berl.) 1997; 38 (5): 411–9.Luscher T. F., Tschudi M. R., Wenzel R. R., Noll G. Endothelial dysfunction and nitrogen monoxide (NO; nitric oxide). Internist (Berl.) 1997; 38 (5): 411–9.Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathology and pharmacology. Pharmacol Rev 1991; 43 (2): 109–42.Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathology and pharmacology. Pharmacol Rev 1991; 43 (2): 109–42.Пизов Н. А., Пизов А. В., Скачкова О. А., Пизова Н. В. Эндотелиальная функция в норме и при патологии. Медицинский совет. 2019; 6: 154–159.Пизов Н. А., Пизов А. В., Скачкова О. А., Пизова Н. В. Эндотелиальная функция в норме и при патологии. Медицинский совет. 2019; 6: 154–159.Каде А. Х., Занин С. А., Губарева Е. А., Туровая А. Ю., Богданова Ю. А., Апсалямова С. О., Мерзлякова С. Н. Физиологические функции сосудистого эндотелия. Фундаментальные исследования. 2011; 11–3: 611–617.Каде А. Х., Занин С. А., Губарева Е. А., Туровая А. Ю., Богданова Ю. А., Апсалямова С. О., Мерзлякова С. Н. Физиологические функции сосудистого эндотелия. Фундаментальные исследования. 2011; 11–3: 611–617.Born G., Schwartz C. Vascular endothelium. Stuttgart: Schattauer, 1997; 390 p.Born G., Schwartz C. Vascular endothelium. Stuttgart: Schattauer, 1997; 390 p.Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharon JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 2006; 5: 4.Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharon JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 2006; 5: 4.Chhabra N. Endothelial dysfunction — A predictor of atherosclerosis. Internet J Med Update. 2009; 4 (1): 33–41.Chhabra N. Endothelial dysfunction — A predictor of atherosclerosis. Internet J Med Update. 2009; 4 (1): 33–41.Strijdom H, Lochner A. Cardiac endothelium: More than just a barrier! SA Heart. 2009; 6 (3): 174–185.Strijdom H, Lochner A. Cardiac endothelium: More than just a barrier! SA Heart. 2009; 6 (3): 174–185.Momboli J. V., Vanhoutte P. M. Endothelial function after converting–enzyme inhibition. Medicographia. 1996; 18 (1): 35–40.Momboli J. V., Vanhoutte P. M. Endothelial function after converting–enzyme inhibition. Medicographia. 1996; 18 (1): 35–40.Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease — a 30th anniversary update. Acta Physiol (Oxf). 2017; 219: 22–96.Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease — a 30th anniversary update. Acta Physiol (Oxf). 2017; 219: 22–96.Flammer A. J., Luscher T. F. Human endothelial dysfunction: EDRFs. Pflugers Arch. 2010; 459: 1005–13.Flammer A. J., Luscher T. F. Human endothelial dysfunction: EDRFs. Pflugers Arch. 2010; 459: 1005–13.Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction: EDCFs. Pflugers Arch. 2010; 459: 1015–23.Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction: EDCFs. Pflugers Arch. 2010; 459: 1015–23.Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004; 44: 2137–2141.Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004; 44: 2137–2141.Kitta Y, Obata JE, Nakamura T, Hirano M, Kodama Y, Fujioka D, Saito Y, Kawabata K, Sano K, Kobayashi T, Yano T, Nakamura K, Kugiyama K. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009; 53: 323–330.Kitta Y, Obata JE, Nakamura T, Hirano M, Kodama Y, Fujioka D, Saito Y, Kawabata K, Sano K, Kobayashi T, Yano T, Nakamura K, Kugiyama K. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009; 53: 323–330.Matsuzawa Y, Sugiyama S, Sugamura K, et al. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol. 2010; 55: 1688–1696.Matsuzawa Y, Sugiyama S, Sugamura K, et al. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol. 2010; 55: 1688–1696.Katz S. D., Hryniewiez K., Hriljac I. et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005; 111: 310–314.Katz S. D., Hryniewiez K., Hriljac I. et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005; 111: 310–314.Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J. Mol. Cell. Cardiol. 1999; 31: 23–37.Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J. Mol. Cell. Cardiol. 1999; 31: 23–37.Bonthu S., Heistad D., Chappel D. et al. Atherosclerosis, Vascular Remodeling, and Impairment of Endothelium–Dependent Relaxation in Genetically Altered Hyperlipidemic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997; 17: 2333–2340.Bonthu S., Heistad D., Chappel D. et al. Atherosclerosis, Vascular Remodeling, and Impairment of Endothelium–Dependent Relaxation in Genetically Altered Hyperlipidemic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997; 17: 2333–2340.Celermajer D., Sorensen K., Gooch V. et al. Non– invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 1111–1115.Celermajer D., Sorensen K., Gooch V. et al. Non– invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 1111–1115.Dimmeler F., Zeiher A. M. Endothelial cells apoptosis in angiogenesis and vessel regression. Circulat. Res. 2000; 87: 434–444.Dimmeler F., Zeiher A. M. Endothelial cells apoptosis in angiogenesis and vessel regression. Circulat. Res. 2000; 87: 434–444.Лизогуб В. Г., Кузько Н. В. Ишемическая болезнь сердца. К.: Здоров’я, 2007; 7–14.Лизогуб В. Г., Кузько Н. В. Ишемическая болезнь сердца. К.: Здоров’я, 2007; 7–14.Лутай М. И. Атеросклероз: современный взгляд на патогенез. Укр. кардіол. журн. 2004; 1: 22–34.Лутай М. И. Атеросклероз: современный взгляд на патогенез. Укр. кардіол. журн. 2004; 1: 22–34.Шабров А. В., Апресян А. Г., Добкес А. Л., Ермолов С. Ю., Ермолова Т. В., Манасян С. Г., Сердюков С. В. Современные методы оценки эндотелиальной дисфункции и возможности их применения в практической медицине. Рациональная фармакотерапия в кардиологии 2016; 12 (6): 733–742.Шабров А. В., Апресян А. Г., Добкес А. Л., Ермолов С. Ю., Ермолова Т. В., Манасян С. Г., Сердюков С. В. Современные методы оценки эндотелиальной дисфункции и возможности их применения в практической медицине. Рациональная фармакотерапия в кардиологии 2016; 12 (6): 733–742.Landmesser U., Hornig B., Drexler H. Endothelial function. A critical determinant in atherosclerosis? Circulation. 2004; 109: II27–II33.Landmesser U., Hornig B., Drexler H. Endothelial function. A critical determinant in atherosclerosis? Circulation. 2004; 109: II27–II33.Соболева Г. Н., Рогоза А. Н., Шумилина М. В., Бузиашвили Ю. И., Карпов Ю. А. Дисфункция эндотелия при артериальной гипертонии: вазопротективные эффекты β-блокаторов нового поколения. Росс. мед. журн. 2001; 9 (18): 754–758.Соболева Г. Н., Рогоза А. Н., Шумилина М. В., Бузиашвили Ю. И., Карпов Ю. А. Дисфункция эндотелия при артериальной гипертонии: вазопротективные эффекты β-блокаторов нового поколения. Росс. мед. журн. 2001; 9 (18): 754–758.Билецкий С. В. Эндотелиальная дисфункция и патология сердечно-сосудистой системы. Журнал «Внутренняя медицина». 2008; 2 (8): 36–41.Билецкий С. В. Эндотелиальная дисфункция и патология сердечно-сосудистой системы. Журнал «Внутренняя медицина». 2008; 2 (8): 36–41.Новикова Н. А. Дисфункция эндотелия — новая мишень медикаментозного воздействия при сердечно-сосудистых заболеваниях. Врач. 2005; 8: 51–53.Новикова Н. А. Дисфункция эндотелия — новая мишень медикаментозного воздействия при сердечно-сосудистых заболеваниях. Врач. 2005; 8: 51–53.Matsuzawa Y 1, Guddeti RR, Kwon TG, Lerman LO, Lerman A. Secondary prevention strategy of cardiovascular disease using endothelialfunction testing. Circ J. 2015; 79 (4): 685–94.Matsuzawa Y 1, Guddeti RR, Kwon TG, Lerman LO, Lerman A. Secondary prevention strategy of cardiovascular disease using endothelialfunction testing. Circ J. 2015; 79 (4): 685–94.Ross R, Glomset J. The pathogenesis of atherosclerosis. N Engl J Med. 1976; 295 (7): 369–77.Ross R, Glomset J. The pathogenesis of atherosclerosis. N Engl J Med. 1976; 295 (7): 369–77.Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23 (2): 168–75.Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003; 23 (2): 168–75.Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17 (11): 1410–22.Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011; 17 (11): 1410–22.Mundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VWM, Iruela-Arispe ML, De Caterina R. Endothelial permeability, LDL deposition, and cardiovascular risk factors–a review. Cardiovasc Res. 2018; 114 (1): 35–52.Mundi S, Massaro M, Scoditti E, Carluccio MA, van Hinsbergh VWM, Iruela-Arispe ML, De Caterina R. Endothelial permeability, LDL deposition, and cardiovascular risk factors–a review. Cardiovasc Res. 2018; 114 (1): 35–52.Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868–74.Libby P. Inflammation in atherosclerosis. Nature. 2002; 420 (6917): 868–74.Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005; 7 (7): 1–24.Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005; 7 (7): 1–24.Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009; 48 (1): 11–22.Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009; 48 (1): 11–22.Hoefer I. E., Steffens S., Ala-Korpela M., et al. Novel methodologies for biomarker discovery in atherosclerosis. European Heart Journal. 2015; 36 (39): 2635–2642.Hoefer I. E., Steffens S., Ala-Korpela M., et al. Novel methodologies for biomarker discovery in atherosclerosis. European Heart Journal. 2015; 36 (39): 2635–2642.Tibaut M., Caprnda M., Kubatka P., et al. Markers of atherosclerosis: part 1 — serological markers. Heart, Lung & Circulation. 2019; 28 (5): 667–677.Tibaut M., Caprnda M., Kubatka P., et al. Markers of atherosclerosis: part 1 — serological markers. Heart, Lung & Circulation. 2019; 28 (5): 667–677.Tibaut M., Caprnda M., Kubatka P., et al. Markers of atherosclerosis: part 2 — genetic and imaging markers. Heart, Lung & Circulation. 2019; 28 (5): 678–689.Tibaut M., Caprnda M., Kubatka P., et al. Markers of atherosclerosis: part 2 — genetic and imaging markers. Heart, Lung & Circulation. 2019; 28 (5): 678–689.Catapano A. L., Pirillo A., Norata G. D. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. British Journal of Pharmacology. 2017; 174 (22): 3973–3985.Catapano A. L., Pirillo A., Norata G. D. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. British Journal of Pharmacology. 2017; 174 (22): 3973–3985.Yousuf O., Mohanty B. D., Martin S. S., et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? Journal of the American College of Cardiology. 2013; 62 (5): 397–408.Yousuf O., Mohanty B. D., Martin S. S., et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? Journal of the American College of Cardiology. 2013; 62 (5): 397–408.Koenig W. High–sensitivity C–reactive protein and atherosclerotic disease: from improved risk prediction to risk–guided therapy. International Journal of Cardiology. 2013; 168 (6): 5126–5134.Koenig W. High–sensitivity C–reactive protein and atherosclerotic disease: from improved risk prediction to risk–guided therapy. International Journal of Cardiology. 2013; 168 (6): 5126–5134.Ridker P. M., Danielson E., Fonseca F. A. H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C–reactive protein. The New England Journal of Medicine. 2008; 359 (21): 2195–2207.Ridker P. M., Danielson E., Fonseca F. A. H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C–reactive protein. The New England Journal of Medicine. 2008; 359 (21): 2195–2207.Ridker P. M., Everett B. M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine. 2017; 377 (12): 1119–1131.Ridker P. M., Everett B. M., Thuren T., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. The New England Journal of Medicine. 2017; 377 (12): 1119–1131.Blaha M. J., Cainzos–Achirica M., Greenland P., et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the multi–ethnic study of atherosclerosis (MESA) Circulation. 2016; 133 (9): 849–858.Blaha M. J., Cainzos–Achirica M., Greenland P., et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease: the multi–ethnic study of atherosclerosis (MESA) Circulation. 2016; 133 (9): 849–858.Bos D., Leening M. J.G., Kavousi M., et al. Comparison of atherosclerotic calcification in major vessel beds on the risk of all–cause and cause-specific mortality: the Rotterdam study. Circulation. Cardiovascular Imaging. 2015; 8 (12).Bos D., Leening M. J.G., Kavousi M., et al. Comparison of atherosclerotic calcification in major vessel beds on the risk of all–cause and cause-specific mortality: the Rotterdam study. Circulation. Cardiovascular Imaging. 2015; 8 (12).Zhao Y., Evans M. A., Allison M. A., et al. Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2019; 282: 202–209.Zhao Y., Evans M. A., Allison M. A., et al. Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: the multi-ethnic study of atherosclerosis. Atherosclerosis. 2019; 282: 202–209.Ridker P. M. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circulation Research. 2016; 118 (1): 145–156.Ridker P. M. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circulation Research. 2016; 118 (1): 145–156.Koenig W., Khuseyinova N., Baumert J., et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006; 26 (12): 2745–2751.Koenig W., Khuseyinova N., Baumert J., et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006; 26 (12): 2745–2751.Jefferis B. J.M.H., Papacosta O., Owen C. G., et al. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis. 2011; 217 (1): 227–233.Jefferis B. J.M.H., Papacosta O., Owen C. G., et al. Interleukin 18 and coronary heart disease: prospective study and systematic review. Atherosclerosis. 2011; 217 (1): 227–233.Li Q., Wang Y., Wang Y., et al. Treg/Th17 ratio acts as a novel indicator for acute coronary syndrome. Cell Biochemistry and Biophysics. 2014; 70 (2): 1489–1498.Li Q., Wang Y., Wang Y., et al. Treg/Th17 ratio acts as a novel indicator for acute coronary syndrome. Cell Biochemistry and Biophysics. 2014; 70 (2): 1489–1498.Liu M., Xu L.-J., Wu J.-X. Changes of circulating CD 4+CD 25+CD 127 low regulatory T cells in patients with acute coronary syndrome and Its significance. Genetics and Molecular Research. 2015; 14 (4): 15930–15936.Liu M., Xu L.-J., Wu J.-X. Changes of circulating CD 4+CD 25+CD 127 low regulatory T cells in patients with acute coronary syndrome and Its significance. Genetics and Molecular Research. 2015; 14 (4): 15930–15936.Filatova A. Y., Pylaeva E. A., Potekhina A. V., et al. Low blood content of IL-10-producing CD 4+ T cells as a risk factor for progression of coronary atherosclerosis. Bulletin of Experimental Biology and Medicine. 2019; 166 (3): 330–333.Filatova A. Y., Pylaeva E. A., Potekhina A. V., et al. Low blood content of IL-10-producing CD 4+ T cells as a risk factor for progression of coronary atherosclerosis. Bulletin of Experimental Biology and Medicine. 2019; 166 (3): 330–333.Lekic A., Brekalo Z., Kvesic A., et al. Crosstalk between enzyme matrix metalloproteinases 2 and 9 and regulatory T cell immunity in the global burden of atherosclerosis. Scandinavian Journal of Immunology. 2017; 86 (1): 65–71.Lekic A., Brekalo Z., Kvesic A., et al. Crosstalk between enzyme matrix metalloproteinases 2 and 9 and regulatory T cell immunity in the global burden of atherosclerosis. Scandinavian Journal of Immunology. 2017; 86 (1): 65–71.Laffont B., Rayner K. J. MicroRNAs in the pathobiology and therapy of atherosclerosis. The Canadian Journal of Cardiology. 2017; 33 (3): 313–324.Laffont B., Rayner K. J. MicroRNAs in the pathobiology and therapy of atherosclerosis. The Canadian Journal of Cardiology. 2017; 33 (3): 313–324.Mudau M., Genis A., Lochner A., Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc. J. Afr. 2012; 23 (4): 222–231.Mudau M., Genis A., Lochner A., Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc. J. Afr. 2012; 23 (4): 222–231.Chhabra N. Endothelial dysfunction — a predictor of atherosclerosis. Internet J. Med. Update. 2009; 4 (1): 33–41.Chhabra N. Endothelial dysfunction — a predictor of atherosclerosis. Internet J. Med. Update. 2009; 4 (1): 33–41.Галенко А. С. Оценка эндотелиальной дисфункции у больных ишемической болезнью сердца и возможности ее фармакологической коррекции: Дис … канд. мед. наук. СПб; 2005.Галенко А. С. Оценка эндотелиальной дисфункции у больных ишемической болезнью сердца и возможности ее фармакологической коррекции: Дис … канд. мед. наук. СПб; 2005.Sever P. S., Dahlof B., Poulter N. R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lover–than–average cholesterol concentrations, in anglo-scandinavial cardiac outcomes trial. Lipid lowering arm (ASCOT-LLA): a multicentre randomizerd trial. Lancet. 2003; 361: 1149–58.Sever P. S., Dahlof B., Poulter N. R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lover–than–average cholesterol concentrations, in anglo-scandinavial cardiac outcomes trial. Lipid lowering arm (ASCOT-LLA): a multicentre randomizerd trial. Lancet. 2003; 361: 1149–58.Colhoun H. M., Betteridge D. J., Durrington P. N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomizerd placebo-controlled trial. Lancet. 2004; 364: 685–96.Colhoun H. M., Betteridge D. J., Durrington P. N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomizerd placebo-controlled trial. Lancet. 2004; 364: 685–96.Заславская Р. М., Лилица Г. В., Щербань Э. Ф. и др. Эффективность метаболической терапии пожилых больных ишемической болезнью сердца. М.: Медпрактика-М; 2010.Заславская Р. М., Лилица Г. В., Щербань Э. Ф. и др. Эффективность метаболической терапии пожилых больных ишемической болезнью сердца. М.: Медпрактика-М; 2010.Koryagina N. A. Effects of mildronate in the complex antiarrhythmic therapy for atrial fibrillation and ventricular arrhythmia in patients with ischemic heart disease. Ph. D. Thesis in Medical Sciences. Perm’; 2007 (in Russian).Koryagina N. A. Effects of mildronate in the complex antiarrhythmic therapy for atrial fibrillation and ventricular arrhythmia in patients with ischemic heart disease. Ph. D. Thesis in Medical Sciences. Perm’; 2007 (in Russian).Pretnar-Oblak J., Zaletel M., Zvan B. et al. Cerebrovascular reactivity to L-arginine in patients with lacunar infraction. Cerebrovasc. Dis. 2006; 21 (3): 180–6.Pretnar-Oblak J., Zaletel M., Zvan B. et al. Cerebrovascular reactivity to L-arginine in patients with lacunar infraction. Cerebrovasc. Dis. 2006; 21 (3): 180–6.Rodriguez J. A., Grau A., Eguinoa E. et al. Dietary supplementation with vitamins С and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. Atherosclerosis. 2002; 165 (1): 33–40.Rodriguez J. A., Grau A., Eguinoa E. et al. Dietary supplementation with vitamins С and E prevents downregulation of endothelial NOS expression in hypercholesterolemia in vivo and in vitro. Atherosclerosis. 2002; 165 (1): 33–40.Clarke R., Armitage J. Vitamin supplements and cardiovascular risk: review of randomized trials of homocysteine-lowering vitamin supplementation. Sem. Thromb. Haemost. 2000; 26 (3): 341–8.Clarke R., Armitage J. Vitamin supplements and cardiovascular risk: review of randomized trials of homocysteine-lowering vitamin supplementation. Sem. Thromb. Haemost. 2000; 26 (3): 341–8.Усманов Р. И., Нуритдинова Н. Б., Зуева Е. Б. Дисфункция эндотелия и ремоделирование левого желудочка при сердечной недостаточности и их коррекция небивололом. Российский кардиологический журнал. 2002; 2: 38–41.Усманов Р. И., Нуритдинова Н. Б., Зуева Е. Б. Дисфункция эндотелия и ремоделирование левого желудочка при сердечной недостаточности и их коррекция небивололом. Российский кардиологический журнал. 2002; 2: 38–41.Matsuda Y., Akita H., Terashima M. et al. Carvedilol improves endothelium-dependent dilatation in patientswith coronary artery disease. Am. Heart J. 2000; 140 (5): 753–9.Matsuda Y., Akita H., Terashima M. et al. Carvedilol improves endothelium-dependent dilatation in patientswith coronary artery disease. Am. Heart J. 2000; 140 (5): 753–9.Bohm F., Beltran E. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J. Intern. Med. 2005; 257 (3): 263–71.Bohm F., Beltran E. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J. Intern. Med. 2005; 257 (3): 263–71.Карпов Ю. А., Соболева Г. Н. Коррекция нарушенной функции сосудистого эндотелия у женщин в период менопаузы: какой препарат лучше? Русский медицинский журнал. 2001; 9 (9): 27–31.Карпов Ю. А., Соболева Г. Н. Коррекция нарушенной функции сосудистого эндотелия у женщин в период менопаузы: какой препарат лучше? Русский медицинский журнал. 2001; 9 (9): 27–31.

The authors declare that there are no conflicts of interest present.